This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) reported a loss of 39 cents per share (excluding restructuring charge) in the three month transition period ended Dec 31, marginally wider than both the Zacks Consensus Estimate and the year-ago loss of 38 cents.
Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.
by Zacks Equity Research
Valeant Pharmaceuticals (VRX) recently announced that the the FDA has approved its Biologic License Application (BLA) for Siliq (brodalumab) injection the treatment of moderate-to-severe plaque psoriasis in adult patients.
Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) reported loss of 7 cents per share in the fourth quarter of 2016 (including the impact of stock-based compensation expenses), narrower than the Zacks Consensus Estimate of a loss of 18 cents.
Ascendis (ASND) Catches Eye: Stock Gains 7.2% in Session
by Zacks Equity Research
Ascendis Pharma A/S (ASND) moved big last session, as its shares rose over 7% on the day.
Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 5.8%
by Zacks Equity Research
Abeona Therapeutics Inc.(ABEO) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
Acorda (ACOR) Catches Eye: Stock Gains 20.8% in Session
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) moved big last session, as its shares rose almost 21% on the day.
Will Cellectis (CLLS) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cellectis SA (CLLS).
The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
Cellectis (CLLS) Shows Strength: Stock Moves 9.1% Higher
by Zacks Equity Research
Cellectis S.A. (CLLS) shares rose over 9% in the last trading session.
Why Cellectis (CLLS) Stock Might be a Great Pick
by Zacks Equity Research
Cellectis (CLLS) in the Medical-Biomedical/Genetics space is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.